Close Menu

NEW YORK (360Dx) – Omega Diagnostics Group said today that it has received CE marking for its Visitect CD4 Advanced Disease test for monitoring people living with HIV.

The test uses a cut-off of 200 CD4 cells/mm³ of blood, the point at which patients' immune systems are so weakened by HIV that they are at risk of infection by other life-threatening diseases, Omega said.

Colin King, CEO of the Scottish diagnostics firm, said in a statement that it intends "to provide easy-to-use, clinically relevant CD4 testing to less advantaged communities around the world."

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

Amid the COVID-19 pandemic, hospitals and intensive care units around the world have been overwhelmed by unprecedented levels of demand. 

Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.

Sponsored by

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.